Adam Maeder
Stock Analyst at Piper Sandler
(3.49)
# 938
Out of 4,983 analysts
94
Total ratings
47.62%
Success rate
6.95%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $8.5 → $7 | $5.94 | +17.85% | 8 | Aug 13, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $233 → $150 | $80.80 | +85.64% | 15 | Aug 5, 2025 | |
| RMD ResMed | Maintains: Neutral | $248 → $270 | $272.60 | -0.95% | 4 | Aug 1, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $83 → $90 | $75.09 | +19.86% | 16 | Jul 25, 2025 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $575 → $595 | $434.50 | +36.94% | 20 | Jul 23, 2025 | |
| RXST RxSight | Maintains: Neutral | $18 → $10 | $9.08 | +10.13% | 2 | Jul 9, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $3.5 → $4 | $3.49 | +14.61% | 1 | Jun 18, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $2.41 | +65.98% | 4 | May 12, 2025 | |
| TCMD Tactile Systems Technology | Downgrades: Neutral | $25 → $14 | $13.80 | +1.45% | 3 | May 6, 2025 | |
| ABT Abbott Laboratories | Reiterates: Overweight | $133 → $145 | $132.76 | +9.22% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $17.43 | +20.48% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $2.77 | +188.81% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $4.65 | +330.11% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.79 | +79.21% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $1.56 | +1,053.85% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $54.93 | +80.23% | 3 | May 5, 2022 |
Vicarious Surgical
Aug 13, 2025
Maintains: Neutral
Price Target: $8.5 → $7
Current: $5.94
Upside: +17.85%
Inspire Medical Systems
Aug 5, 2025
Maintains: Overweight
Price Target: $233 → $150
Current: $80.80
Upside: +85.64%
ResMed
Aug 1, 2025
Maintains: Neutral
Price Target: $248 → $270
Current: $272.60
Upside: -0.95%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $83 → $90
Current: $75.09
Upside: +19.86%
Intuitive Surgical
Jul 23, 2025
Reiterates: Overweight
Price Target: $575 → $595
Current: $434.50
Upside: +36.94%
RxSight
Jul 9, 2025
Maintains: Neutral
Price Target: $18 → $10
Current: $9.08
Upside: +10.13%
Sight Sciences
Jun 18, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $3.49
Upside: +14.61%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $2.41
Upside: +65.98%
Tactile Systems Technology
May 6, 2025
Downgrades: Neutral
Price Target: $25 → $14
Current: $13.80
Upside: +1.45%
Abbott Laboratories
Apr 17, 2025
Reiterates: Overweight
Price Target: $133 → $145
Current: $132.76
Upside: +9.22%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $17.43
Upside: +20.48%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $2.77
Upside: +188.81%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $4.65
Upside: +330.11%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.79
Upside: +79.21%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $1.56
Upside: +1,053.85%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $54.93
Upside: +80.23%